Actively Enrolling
The AlzMatch Study tests whether a single blood test, collected at community-based laboratories, can help speed clinical trial enrollment by identifying people most likely to have amyloid in the brain. Brain amyloid is a protein that builds up in people who may go on to have memory problems because of Alzheimer’s disease. Many studies are looking for individuals who have an increased likelihood of having amyloid, and the AlzMatch Study seeks to simplify the screening process for these studies using a blood test. AlzMatch is inviting participants who are registered in the Alzheimer Prevention Trials (APT) Webstudy and are over 50 years of age, with no diagnosis of dementia. After consent, the primary measures are engagement of eligible participants and collection of blood samples. All participants will be informed of their eligibility to be screened for a clinical study. If eligible and agree to referral, participants will be connected to a local research site for in-person evaluation. Learn more about the APT Webstudy at: aptwebstudy.org
